Percentage of female patients, age = 18 at diagnosis, who have their first diagnosis of cancer (epithelial malignancy), at AJCC T1cN0M0 or stage IB to IIIC, whose primary tumor is of the breast, and is progesterone or estrogen receptor positive with adjuvant hormonal therapy (recommended or administered) within 1 year (365 days) of diagnosis
Measure Specs
General Information
Numerator
Adjuvant hormonal therapy is administered within 1 year (365 days) of the date of diagnosis or it is recommended but not administered
Denominator
Include if all of the following characteristics are identified:
Women
Age = 18 at time of diagnosis
Known or assumed to be first or only cancer diagnosis
Epithelial malignancy only
Invasive tumors
Primary tumors of the breast
AJCC T1cN0M0 or Stage IB – IIIC
Primary tumor is estrogen receptor positive or progesterone receptor positive
All or part of 1st course of treatment performed at the reporting facility
Known to be alive within 1 year (365 days) of date of diagnosis
Surgical procedure of the primary site
Exclusions
Exclude, if any of the following characteristics are identified:
Men
Under age 18 at time of diagnosis
Second or subsequent cancer diagnosis
Tumor not originating in the breast
Non-epithelial malignancies, exclude malignant phyllodes tumors; 8940 - Mixed tumor, malignant, NOS; 8950 - Mullerian mixed tumor; 8980 - Carcinosarcoma; 8981 - Carcinosarcoma, embryonal
Non-invasive tumors
Stage 0, in-situ tumor
Stage IV, metastatic tumor
Primary tumor is estrogen receptor negative and progesterone receptor negative
None of 1st course therapy performed at reporting facility
Died within 1 year (365 days) of diagnosis,
Patient enrolled in a clinical trial that directly impacts delivery of the standard of care
No surgical procedure of the primary site
Not AJCC T1cN0M0 or not AJCC stage IB-IIIC
Public Comments